Stock Alert: Sarepta Therapeutics Up 9%

(RTTNews) - Shares of Sarepta Therapeutics, Inc. (SRPT) are currently gaining about 10% after the company announced positive results from a study of investigational treatment for a rare muscle disorder.

SRPT is currently trading at $82.18, up $7.06 or 9.39%, on the Nasdaq.

Sarepta Therapeutics announced positive 12-week expression and safety results from the first 11 participants enrolled in Study SRP-9001-103, an open-label study known as ENDEAVOR being conducted in partnership with Roche.

Sarepta said it investigational gene therapy for the treatment of duchenne muscular dystrophy, SRP-9001, demonstrated robust expression and consistent safety profile using the company's commercial process material.

SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.